Development, Optimization, and Evaluation of Paroxetine HCl-Loaded PCL Polymeric Nanoparticles A NOVEL DRUG DELIVERY PLATFORM FOR COLORECTAL CANCER THERAPY

hanchate, atharva; kulkarni, parth

doi:https://doi.org/10.55041/ijsmt.v2i6.136

Plagiarism Passed

Peer reviewed

Open Access

DEVELOPMENT, OPTIMIZATION, AND EVALUATION OF PAROXETINE HCL-LOADED PCL POLYMERIC NANOPARTICLES A NOVEL DRUG DELIVERY PLATFORM FOR COLORECTAL CANCER THERAPY

AUTHORS:

atharva hanchate

parth kulkarni

Mentor

Affiliation

DOI: 10.55041/ijsmt.v2i6.136

CC BY 4.0 License:

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

DOWNLOAD ARTICLE

REVIEW REPORT

CITE THIS ARTICLE

Abstract

Colorectal cancer (CRC) remains an escalating clinical crisis globally, characterized by formidable mortality rates and a desperate need for enhanced therapeutic paradigms. Current clinical interventions are restricted by severe systemic toxicities, non-specific biodistribution patterns, and the rapid emergence of multidrug resistance (MDR) phenotypes within tumor cells.

However, translating conventional oral paroxetine into a viable oncology therapeutic faces physiological bottlenecks, including poor solid-tumor bioaccumulation and volatile pharmacokinetic tracking. To bypass these limitations, this study utilizes biodegradable Polycaprolactone (PCL) matrices to construct nanoscale delivery vehicles designed to protect the payload, control systemic release, and enhance tumor accumulation via the Enhanced Permeability and Retention (EPR) effect.

Keywords

Article Information

Article Metrics

Article Views

PDF Downloads

HOW TO CITE

References

Ethics and Compliance

✓ All ethical standards met

This article has undergone plagiarism screening and double-blind peer review. Editorial policies have been followed. Authors retain copyright under CC BY-NC 4.0 license. The research complies with ethical standards and institutional guidelines.

Indexed In